Loading...
Loading...
Genentech, a member of the Roche Group
RHHBY,
today announced positive results from a pivotal Phase III study that
evaluated the investigational medicine ocrelizumab in people with
primary progressive multiple sclerosis (PPMS). The study (called
ORATORIO) met its primary endpoint, showing treatment with ocrelizumab
significantly reduced the progression of clinical disability sustained
for at least 12 weeks compared with placebo, as measured by the Expanded
Disability Status Scale (EDSS).
Overall, the incidence of adverse events associated with ocrelizumab was
similar to placebo; the most common adverse events were mild-to-moderate
infusion-related reactions. The incidence of serious adverse events
associated with ocrelizumab, including serious infections, was also
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in